{
    "nct_id": "NCT05651711",
    "official_title": "A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)",
    "inclusion_criteria": "* Age ≥ 18 years (or ≥ legal adult age within the country if it is older than 18 years at signing of informed consent) with a diagnosis of AD according to the AAD Consensus Criteria (2014) present for at least 12 months\n* History of inadequate response to TCS (Topical Corticosteroid) of medium or higher potency (with or without topical calcineurin inhibitors [TCI]) as appropriate or for whom topical treatments are otherwise medically inadvisable (eg, because of important side effects or safety risks).\n* EASI score ≥16\n* vIGA-AD score ≥3\n* ≥10% body surface area (BSA) of AD involvement\n* Worst pruritus numerical rating scale ≥ 4\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 100 Years",
    "exclusion_criteria": "* Treatment with a biological product within 12 weeks or 5 half-lives, whichever is longer, prior to Day 1\n* Treatment with any of the following medications or therapies within 4 weeks or 5 half-lives, whichever is longer, prior to Day 1:\n\n  * Systemic corticosteroids\n  * Systemic immunosuppressants\n  * Phototherapy\n  * Oral or topical Janus kinase inhibitors\n* Treatment with any of the following medications or therapies within 1 week, prior to Day 1:\n\n  * TCS of any potency\n  * TCI\n  * Topical phosphodiesterase type 4 (PDE4) inhibitors\n  * Other topical immunosuppressive agents\n  * Combination agents including TCS of any potency or TCI, PDE4 inhibitors, or other immunosuppressive agents",
    "miscellaneous_criteria": ""
}